Affordability and access issues around expensive drugs

The challenge of affording life-saving specialty medications remains a pressing issue for many patients, exemplified by the experience of Jayant Mishra of Mission Viejo, California. In 2025, Jayant developed a progressive medical condition characterized by scaly, itchy red patches requiring an expensive, specialized drug therapy to manage symptoms and prevent further deterioration. Initially, a pharmaceutical copay assistance card enabled him to access this costly treatment, easing his financial burden and providing crucial relief.

The Promise and Fragility of Copay Assistance

Copay cards are intended to reduce out-of-pocket expenses for patients prescribed high-cost medications, often making otherwise inaccessible treatments affordable in the short term. For Jayant, this assistance was a lifeline—without it, he might never have started therapy. However, copay cards come with inherent limitations:

• Usage Caps and Eligibility Restrictions: Many programs limit total benefits or impose strict eligibility criteria, making sustained support uncertain.
• Sudden Program Discontinuation: Changes in funding, insurer policies, or manufacturer decisions can abruptly end assistance, as happened in Jayant’s case.
• Temporary Nature of Relief: These cards are stopgap measures rather than permanent solutions, leaving patients vulnerable once benefits expire.

When Jayant’s copay card program was restricted and ultimately discontinued, he faced the full retail cost of his medication—an amount he could not afford. This financial strain jeopardized his adherence to the therapy regimen, increasing risks of dose reductions, delayed refills, or complete cessation of treatment. The consequences of such interruptions are severe, often triggering disease progression, heightened hospitalizations, and ultimately greater overall healthcare costs.

Systemic Implications Highlighted by Individual Struggles

Jayant’s ordeal is far from unique and reveals broader systemic flaws in the financing and accessibility of specialty drugs:

• Reliance on Temporary, Unstable Support Mechanisms: Patients depend heavily on copay assistance that may vanish without warning.
• Adherence and Health Outcome Risks: Financial barriers directly impact medication adherence, worsening health trajectories.
• Economic Paradox: While copay cards reduce immediate out-of-pocket costs, interruptions in therapy may lead to more expensive healthcare utilization downstream.

These challenges underscore the urgent need for more sustainable and predictable affordability solutions.

Emerging Developments Offer Hope for Long-Term Change

Amid these affordability struggles, promising industry advancements could reshape access to expensive therapies. A notable recent development is Amgen Inc.’s completion of a Phase 3 trial for ABP 206, a biosimilar candidate to Bristol-Myers Squibb’s Opdivo (nivolumab), a widely used but costly immunotherapy drug.

• What This Means: Biosimilars are designed to be clinically equivalent to branded biologics but typically enter the market at lower prices, offering a pathway to reduce drug costs over time.
• Potential Impact: Successful biosimilars like ABP 206 could significantly increase competition, driving down prices and expanding patient access to vital treatments.
• Industry Momentum: Amgen’s progress reflects a broader push to develop biosimilars for high-cost specialty drugs, which could alleviate some of the financial pressures faced by patients like Jayant.

While such innovations signal progress, they do not immediately solve the affordability crisis. Stable patient support programs, greater pricing transparency, and innovative payment models—such as value-based agreements or subscription payment plans—are still essential to bridge gaps in access now.

Looking Forward: Addressing the Affordability Gap

Jayant Mishra’s story remains a poignant reminder of the fragility of current patient assistance mechanisms and the high stakes involved when they fail. To ensure that cost does not become a barrier to life-saving therapies, stakeholders must:

• Develop Durable Affordability Programs: Programs with predictable, long-term funding and clear eligibility to prevent sudden loss of support.
• Enhance Drug Pricing Transparency: Policies that clarify how prices are set and how discounts or assistance are applied.
• Encourage Innovative Payment Models: Approaches that share financial risk between manufacturers, payers, and patients, aligning costs with clinical outcomes.
• Support Biosimilar Adoption: Facilitate regulatory pathways and market uptake to lower biologic drug prices sustainably.

In conclusion, while copay cards offer important short-term relief, they are insufficient as a standalone solution. Industry advancements like Amgen’s biosimilar candidate provide promising avenues for reducing drug costs in the future, but comprehensive systemic reforms are critical to ensure patients like Jayant can consistently afford and adhere to essential therapies without jeopardizing their health.